Evidence map›Paper›PMID 24062259›Full record

ArticleMedical oncology (Northwood, London, England)2013

Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type.

Li Yang, Hong Liu, Xiao-hong Xu, Xin-feng Wang, Hong-ming Huang, Wen-yu Shi, Sheng-hua Jiang

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Management of NK/T-Cell Lymphoma, Nasal Type.Journal of oncology practice · 2019
    Review
  10. Article
  11. Article
  12. Current status and progress of lymphoma management in China.International journal of hematology · 2018
    Review
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Primary bone natural killer/T cell lymphoma, nasal type without EBV infection: a case report.International journal of clinical and experimental pathology · 2015
    Article
  19. Fluoro-deoxy glucose positron emission tomography-computed tomography in a case of natural killer/T-cell lymphoma with bilateral adrenal involvement.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Li YangHematology Department, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China, bulade.peter@outlook.com.
Hong Liu
Xiao-hong Xu
Xin-feng Wang
Hong-ming Huang
Wen-yu Shi
Sheng-hua Jiang

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extranodal natural killer/T cell lymphomas, nasal type (ENKLs), which are a group of non-Hodgkin lymphomas with poor prognoses, are much more common in China than in Western countries. Here, we retrospectively assessed the impact of two treatment regimens on clinical response and survival among 42 ENKL patients. All patients were diagnosed with stage IV, relapsed, or refractory ENKL. Twenty patients received modified SMILE (consisting of L-asparaginase, methotrexate, ifosphamide, etoposide, and dexamethasone) chemotherapy, and 22 control patients received CHOP (consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone) treatment. Higher complete response (CR) and overall response rates (ORR) (CR 45.0 vs. 13%, ORR 70 vs. 36%) were observed among the patients treated with the modified SMILE regimen (Fisher's exact = 0.040, Pearson χ(2) P = 0.030). Similarly, a higher ORR rate was observed among Epstein-Barr virus-positive patients (ORR 50.0 vs. 18.0%, Fisher's exact = 0.049). The treatment group was also significantly associated with longer overall survival (OS) and progression-free survival (PFS) (Log-rank, P = 0.0341, P = 0.0142, respectively), but OS did not seem to be longer. Treatment-related toxicity was monitored in all patients throughout the protocol. There were no significant differences in the incidence of hematological and non-hematological toxicities between the two groups (P < 0.05), with the exception of peripheral neuropathy (treatment = 0 control = 5, Fisher's exact = 0.049).

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyDisease-Free SurvivalFemaleHumansLymphoma, Extranodal NK-T-CellMaleMiddle AgedNeoplasm Recurrence, LocalNose NeoplasmsPrognosisRetrospective StudiesYoung Adult

Identifiers

PMID24062259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.